Get the Stockscreener App
1.26
1.56%
-0.02
After Hours:
1.29
0.03
+2.38%
Pmv Pharmaceuticals Inc stock is traded at $1.26, with a volume of 163.29K.
It is down -1.56% in the last 24 hours and down -14.86% over the past month.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
See More
Previous Close:
$1.28
Open:
$1.28
24h Volume:
163.29K
Relative Volume:
0.25
Market Cap:
$67.20M
Revenue:
-
Net Income/Loss:
$-78.34M
P/E Ratio:
-0.8503
EPS:
-1.4819
Net Cash Flow:
$-75.02M
1W Performance:
-2.33%
1M Performance:
-14.86%
6M Performance:
-4.55%
1Y Performance:
+40.00%
1-Day Range:
$1.25
$1.31
1-Week Range:
$1.22
$1.35
52-Week Range:
$0.85
$1.88
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
Name
Pmv Pharmaceuticals Inc
Sector
Industry
Phone
(609) 642-6670
Address
400 ALEXANDER PARK DRIVE, PRINCETON
Compare PMVP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
1.26 | 68.26M | 0 | -78.34M | -75.02M | -1.4819 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Upgrade | Oppenheimer | Perform → Outperform |
| May-13-24 | Initiated | Craig Hallum | Buy |
| Apr-12-24 | Initiated | Jefferies | Buy |
| Dec-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Mar-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-22-21 | Upgrade | Goldman | Neutral → Buy |
| Aug-19-21 | Initiated | Oppenheimer | Perform |
| Aug-02-21 | Initiated | Guggenheim | Buy |
| Jul-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Cowen | Outperform |
| Oct-20-20 | Initiated | Evercore ISI | Outperform |
| Oct-20-20 | Initiated | Goldman | Neutral |
View All
Pmv Pharmaceuticals Inc Stock (PMVP) Latest News
PMV Pharmaceuticals (PMVP) Slips to $1.26 as Cautious Trading Puts Support to the TestCalendar Spread Trade - Newser
PMV Pharmaceuticals, Inc.Common Stock (Nasdaq:PMVP) Stock Quote - FinancialContent
Number of shareholders of PMV Pharmaceuticals, Inc. – NASDAQ:PMVP - TradingView
Euclidean Capital reports 2.6M shares in PMVP (PMVP) - Stock Titan
PMV Pharmaceuticals (PMVP) Q1 2026 Earnings: Why the Beat MattersShared Trade Ideas - newser.com
PMV Pharmaceuticals (PMVP) price target decreased by 37.50% to 4.84 - MSN
PMVP Maintains Outperform Rating by Oppenheimer -- Price Target Lowered to $5.00 - GuruFocus
Oppenheimer Maintains PMV Pharmaceuticals(PMVP.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
12 Health Care Stocks Moving In Wednesday's After-Market SessionAquestive Therapeutics (NASDAQ:AQST) - Benzinga
TradingKey - TradingKey
PMVP Advances PYNNACLE Study and NDA Submission Timeline - GuruFocus
PMV Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
PMV Pharmaceuticals stock (US7301281085): Q1 2026 results and rezatapopt orphan drug nod - AD HOC NEWS
PMV Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
PMV Pharmaceuticals 1Q Loss/Shr 34c >PMVP - Moomoo
PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights - The Manila Times
PMV Pharmaceuticals' Q1 net loss widens - TradingView
PMV Pharmaceuticals 1Q 2026: Net loss $18M, EPS $(0.34) — 10-Q Summary - TradingView
PMV Pharmaceuticals 1Q Loss $18M >PMVP - Moomoo
PMV Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
8-K: PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlightsmoomoo - Moomoo
PMV Pharmaceuticals (NASDAQ: PMVP) reports Q1 2026 loss and details rezatapopt progress - Stock Titan
PMV Pharmaceuticals (NASDAQ: PMVP) Q1 2026 loss, strong rezatapopt data and orphan status - Stock Titan
PMV Pharmaceuticals (PMVP) Eps Diluted (TTM) - Zacks Investment Research
PMV Pharmaceuticals Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Sio Capital (PMVP) discloses 3,076,580 shares, 5.77% stake in PMV Pharmaceuticals - Stock Titan
PMV Pharmaceuticals (PMVP) to Release Earnings on Friday - MarketBeat
PMVP PMV Pharmaceuticals beats Q4 2025 EPS estimates by 17.7 percent, shares hold steady in today’s trading.Pre Announcement - newser.com
Short Interest in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Increases By 48.3% - MarketBeat
PMV Pharmaceuticals (PMVP) posts narrower than expected Q4 2025 loss, shares rise 1.37 percent in today's trading.Community Exit Signals - Newser
Is PMV Pharmaceuticals (PMVP) stock priced below intrinsic value (Institutional Demand) 2026-04-22Social Buy Zones - Cổng thông tin điện tử tỉnh Lào Cai
PMV Pharmaceuticals names Laurie Stelzer as board chair - Investing.com
PMV Pharmaceuticals chair Rich Heyman to depart, Laurie Stelzer to succeed - TipRanks
PMV Pharmaceuticals names Laurie Stelzer as board chair By Investing.com - Investing.com Canada
[ARS] PMV Pharmaceuticals, Inc. SEC Filing - Stock Titan
PMV Pharmaceuticals Announces Board Chair Transition - Weekly Voice
The Beauty Health Company Announces Corporate Rebrand to SkinHealth Systems, Reflecting Evolution into a Clinically Driven, Science-Backed Medical Aesthetics Platform - Weekly Voice
As PMV nears a 2027 drug filing, its board chair changes hands - Stock Titan
Board shifts and pay vote in PMV Pharmaceuticals (NASDAQ: PMVP) 2026 proxy - Stock Titan
Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Invest In Growth? - Yahoo Finance
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
PMV Pharmaceuticals (NASDAQ:PMVP) Stock Rating Upgraded by Evercore - MarketBeat
PMV Pharmaceuticals price target lowered to $4 from $16 at Evercore ISI - TipRanks
Stock List: Research Stocks from Around the World - GuruFocus
GUTS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Is PMV Pharmaceuticals (PMVP) Stock Breaking Resistance | Price at $1.29, Down 0.77%Crowd Entry Points - Newser
Energy Moves: Will PMV Pharmaceuticals Inc outperform its industry peers2026 Momentum & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Dividend Watch: Is PMV Pharmaceuticals Inc exposed to currency risksQuarterly Earnings Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Quarterly Recap: Is Edgewell Personal Care Company forming bullish engulfing patternsIPO Watch & Growth Focused Entry Reports - baoquankhu1.vn
PLRX PE Ratio & Valuation, Is PLRX Overvalued - Intellectia AI
PMVP Stock Analysis: PMV Pharmaceuticals Inc Biotech Performance At 1.34 Price - Newser
Pmv Pharmaceuticals Inc Stock (PMVP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pmv Pharmaceuticals Inc Stock (PMVP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
Oct 23 '25 |
Sale |
1.52 |
1,000,000 |
1,520,000 |
4,975,291 |
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):